All Global Research articles can be read in 27 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).
***
Corporate news sources are reporting that Austria has suspended their roll-out of the experimental AstraZeneca COVID vaccines after a 49-year-old nurse has died “as a result of severe coagulation disorders,” and a 35-year-old nurse developed a pulmonary embolism following the COVID injections.
A pulmonary embolism is an acute lung disease caused by a dislodged blood clot.
Both nurses reportedly worked at the Zwettl clinic in Lower Austria province.
The Austrian Federal Office for Safety in Health Care (BASG) said blood clotting was not among the known side effects of the AstraZeneca vaccine.
An AstraZeneca spokesman said: “There have been no confirmed serious adverse events associated with the vaccine.”
However, the statistics published by the UK Government’s Medicines and Healthcare products Regulatory Agency last week reported 244 deaths and 157,637 injuries following injections of the experimental AstraZeneca vaccine in the UK.
A recent CDC report in the U.S. found that 62% of nursing home workers are refusing the experimental Pfizer and Moderna COVID “vaccines.” (Source.)
Since long-term healthcare residents were targeted as among the first to receive the new experimental COVID vaccines in almost every country that has begun COVID injections, and where many deaths are being reported following the injections, it is easy to understand this “vaccine hesitancy” among healthcare workers who are observing these deaths and reactions firsthand.
*
Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.
Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the
copyright owner.
